Zogenix, Inc. (ZGNX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZGNX POWR Grades
- ZGNX scores best on the Growth dimension, with a Growth rank ahead of 64.45% of US stocks.
- ZGNX's strongest trending metric is Stability; it's been moving up over the last 31 weeks.
- ZGNX ranks lowest in Momentum; there it ranks in the 5th percentile.
ZGNX Stock Summary
- ZGNX's price/sales ratio is 37.07; that's higher than the P/S ratio of 93.33% of US stocks.
- With a year-over-year growth in debt of 1,169.84%, Zogenix Inc's debt growth rate surpasses 98.62% of about US stocks.
- Revenue growth over the past 12 months for Zogenix Inc comes in at 432.53%, a number that bests 98.3% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Zogenix Inc are ASMB, RCUS, QURE, ALPN, and VSTM.
- Visit ZGNX's SEC page to see the company's official filings. To visit the company's web site, go to www.zogenix.com.
ZGNX Stock Price Chart Interactive Chart >
ZGNX Price/Volume Stats
|Current price||$18.20||52-week high||$32.42|
|Prev. close||$17.92||52-week low||$16.73|
|Day high||$18.31||Avg. volume||782,163|
|50-day MA||$18.54||Dividend yield||N/A|
|200-day MA||$20.23||Market Cap||1.02B|
Zogenix, Inc. (ZGNX) Company Bio
Zogenix develops and commercializes therapies for the treatment of central nervous system disorders. The company was founded in 2006 and is based in San Diego, California.
ZGNX Latest News Stream
|Loading, please wait...|
ZGNX Latest Social Stream
View Full ZGNX Social Stream
Latest ZGNX News From Around the Web
Below are the latest news stories about Zogenix Inc that investors may wish to consider to help them evaluate ZGNX as an investment opportunity.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
EMERYVILLE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a virtual fireside chat on Thursday, May 13, 2021, at the BofA Securities 2021 Healthcare Conference. Zogenix Presentation DetailsDate:Thursday, May 13, 2021Time:3:30 PM Eastern Time The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com. About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with th...
Zogenix's Fintepla Associated With Improvements in Seizure Control, Executive Functions In Childhood Epilepsy Disorder
Zogenix Inc (NASDAQ: ZGNX) has announced new data showing the positive impact of treatment with Fintepla (fenfluramine) on everyday executive function for children and young adults with Lennox-Gastaut syndrome (LGS), a rare and severe kind of childhood epilepsy characterized by different types of seizures. These posthoc analysis data were presented at the virtual American Academy of Neurology (AAN) Annual Meeting. The objective of this posthoc analysis was to assess the impact of the treatment with abilities to self-regulate behavior, emotions, and cognition as part of a 14-week Phase 3 trial in 263 LGS patients aged 2-35 years. More LGS study patients treated with Fintepla showed improvement in behavior, emotion, and cognitive function in intractable epilepsy and other developmental co...
Zogenix Presents New Data at Virtual AAN 2021 Showing Improved Executive Function in Lennox-Gastaut Syndrome (LGS) Patients Treated with FINTEPLA® (Fenfluramine) Oral Solution
LGS is one of the most challenging developmental and epileptic encephalopathies to manage because of high seizure frequency and significant neurodevelopmental impairment.More LGS study patients treated with FINTEPLA (fenfluramine) showed improvement in each of the BRIEF 2 indexes that have been used to assess behavior, emotion, and cognitive function in intractable epilepsy and other developmental conditions.Improvement was statistically significant for Cognition (27% vs 13% placebo, p=0.046) and the Global Executive Composite score (25% vs 11% placebo, p=0.034), where approximately twice as many patients achieved clinically meaningful improvement. EMERYVILLE, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease th...
Zogenix to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 6
EMERYVILLE, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the first quarter ended March 31, 2021 and host a corporate update conference call and webcast after the market close on Thursday, May 6, 2021, at 4:30 PM Eastern Time. Conference Call DetailsThursday, May 6, at 4:30 PM Eastern Time / 1:30 PM Pacific TimeToll Free: 877-846-2690 International: 416-981-9029Conference ID: 21993693Webcast: http://public.viavid.com/index.php?id=144590 About Zogenix Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare...
ZGNX Price Returns